Pulmonary toxicity of induction chemotherapy prior to standard or high- dose chemotherapy with autologous hematopoietic support

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 1, 2000, Pages 17-25

  Bhalla, Karan S ^a   Wilczynski, Stephen ^a   Abushamaa, Amir M ^a   Petros, William P ^a   McDonald, Carolyn S ^a   Loftis, Jennifer S ^a   Chao, Nelson J ^a   Vredenburch, James J ^a   Folz, Rodney J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG FUNCTION TEST; LUNG TOXICITY; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033964488     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.1.9903059     Document Type: Article

References (35)

1. 1. Peters, W. P., M. Ross, J. J. Vredenburgh, B. Meisenberg, L. B. Marks, E. Winer, J. Kurtzberg, J. R. C. Bast, R. Jones, E. Shpall, K. Wu, G. Rosner, C. Gilbert, B. Mathias, D. Coniglio, W. Petros, I. C. Henderson, L. Norton, R. B. Weiss, D. Budman, and D. Hurd. 1993. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol. 11:1132-1143.
2. 2. Antman, K. H., P. A. Rowlings, W. P. Vaughan, C. J. Pelz, J. W. Fay, K. K. Fields, C. O. Freytes, R. P. Gale, B. E. Hillner, H. K. Holland, M. J. Kennedy, J. P. Klein, H. M. Lazarus, P. L. McCarthy, Jr., R. Saez, G. Spitzer, E. A. Stadtmauer, S. F. Williams, S. Wolff, K. A. Sobocinski, J. O. Armitage, and M. M. Horowitz. 1997. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J. Clin. Oncol. 15:1870-1879.
3. 3. Rahman, Z. U., G. N. Hortobagyi, A. U. Buzdar, and R. Champlin. 1998. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat. Rev. 24:249-263.
4. 4. Hurd, D. D., and W. P. Peters. 1995. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B. J. Natl. Cancer. Inst. Monogr. 19:41-44.
5. 5. Aisner, J., C. Cirrincione, M. Perloff, M. Perry, D. Budman, J. Abrams, L. Panasci, H. Muss, M. Citron, J. Holland, et al. 1995. Combination chemotherapy for metastatic or recurrent carcinoma of the breast - a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J. Clin. Oncol. 13:1443-1452.
6. 6. Schwartzberg, L. S., R. Birch, W. H. West, K. W. Tauer, F. Witllin, R. Leff, L. Campos, W. Rymer, P. Carter, M. Mangum, F. A. Greco, J. Hainsworth, E. Raefsky, R. Blanco, C. D. Buckner, and C. H. Weaver. 1998. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-ITI breast cancer: outpatient administration in community cancer centers. Am. J. Clin. Oncol. 21:523-531.
7. 7. Todd, N. W., W. P. Peters, A. H. Ost, V. L. Roggli, and C. A. Piantadosi. 1993. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am. Rev. Respir. Dis. 147:1264-1270.
8. 8. Jones, R. B., S. Matthes, E. J. Shpall, J. H. Fisher, S. M. Stemmer, C. Dufton, J. K. Stephens, and S. I. Bearman. 1993. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J. Natl. Cancer Inst. 85:640-647.
9. 9. Chap, L., R. Shpiner, M. Levine, L. Norton, M. Lill, and J. Glaspy. 1997. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant. 20:1063-1067.
10. 10. Wilczynski, S. W., J. J. Erasmus, W. P. Petros, J. J. Vredenburgh, and R. J. Folz. 1998. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am. J. Respir. Crit. Care Med. 157:565-573.
11. 11. American Thoracic Society. 1995. Single-breath carbon monoxide diffusing capacity (transfer factor). Am. J. Respir. Crit. Care Med. 152: 2185-2198.
12. 12. American Thoracic Society. 1995. Standardization of spirometry. Am. J. Respir. Crit. Care Med. 152:1107-1136.
13. 13. Crapo, R. O., A. H. Morris, and R. M. Gardner. 1981. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 123:659-664.
14. 14. Crapo, R. O., and A. H. Morris. 1981. Standardized single breath normal values for carbon monoxide diffusing capacity. Am. Rev. Respir. Dis. 123:185-189.
15. 15. Robbins, R. A., A. A. Floreani, S. E. Buchalter, J. R. Spurzem, J. H. Sisson, and S. I. Rennard. 1992. Pulmonary complications of transplantation. Annu. Rev. Med. 43:425-435.
16. 16. Breuer, R., I. S. Lossos, N. Berkman, and R. Or. 1993. Pulmonary complications of bone marrow transplantation. Respir. Med. 87:571-579.
17. 17. Ettinger, N. A., and E. P. Trulock. 1991. Pulmonary considerations of organ transplantation: part 2. Am. Rev. Respir. Dis. 144:213-223.
18. 18. Wingard, J. R., E. D. Mellits, M. B. Sostrin, D. Y.-H. Chen, W. H. Burns, G. W. Santos, H. M. Vriesendorp, W. E. Beschorner, and R. Saral. 1988. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine 67:175-186.
19. 19. Clark, J. G., J. A. Hansen, M. I. Hertz, R. Parkman, L. Jensen, and H. H. Peavy. 1993. Idiopathic pneumonia syndrome after bone marrow transplantation. Am. Rev. Respir. Dis. 147:1601-1606.
20. 20. Elias, J. A., and V. Lentz. 1990. IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J. Immunol. 145:161-166.
21. 21. Kotloff, R. M., J. Little, and J. A. Elias. 1990. Human alveolar macrophage and blood monocyte interleukin-6 production. Am. J. Respir. Cell Mol. Biol. 3:497-505.
22. 22. Loppnow, H., and P. Libby. 1989. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol 122:493-503.
23. 23. Zitnik, R. J., and J. A. Elias. 1993. Interleukin-6 and the lung. In J. Kelley, editor. Cytokines of the Lung, Lung Biology in Health and Disease. Marcel Dekker, Inc., New York. 229-280.
24. 24. DeMarco, D., S. L. Kunkel, R. M. Strieter, M. Basha, and R. B. Zurier. 1991. Interleukin-1 induced gene expression of neutrophil activating protein (interleukin-8) and monocyte chemotactic peptide in human synovial cells. Biochem. Biophys. Res. Commun. 174:411-416.
25. 25. Larsen, C. G., A. O. Anderson, E. Appella, J. J. Oppenheim, and K. Matsushima. 1989. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243:1464-1466.
26. 26. Hunninghake, G. W., J. E. Gadek, T. J. Lawley, and R. G. Crystal. 1981. Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 68:259-269.
27. 27. Hunninghake, G. W., K. C. Garrett, H. B. Richerson, J. C. Fantone, P. A. Ward, S. I. Rennard, P. B. Bitterman, and R. G. Crystal. 1984. Pathogenesis of the granulomatous lung diseases. Am. Rev. Respir. Dis. 130: 476-496.
28. 28. Hofsli, E., J. Lamvik, and J. Nissen-Meyer. 1988. Evidence that tumour necrosis factor (TNF) is not constitutively present in vivo: the association of TNF with freshly isolated monocytes reflects a rapid in vitro production. Scand. J. Immunol. 28:435-441.
29. 29. Ulich, T. R., K. Z. Guo, B. Irwin, D. G. Remick, and G. N. Davatelis. 1990. Endotoxin-induced cytokine gene expression in vivo: II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression. Am. J. Pathol. 137:1173-1185.
30. 30. Beutler, B., D. Greenwald, J. D. Hulmes, M. Chang, Y. C. Pan, J. Mathison, R. Ulevitch, and A. Cerami. 1985. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552-554.
31. 31. Morse, C. C., C. Sigler, S. Lock, P. J. Hakkinen, W. M. Haschek, and H. P. Witschi. 1985. Pulmonary toxicity of cyclophosphamide: a 1-year study. Exp. Mol. Palhol. 42:251-260.
32. 32. Cooper, J. A. D., Jr., and W. W. Marrill. 1989. Modulation of endoper-oxide product levels and cyclophosphamide induced injury by glutathione repletion. J. Appl. Physiol. 67:2316-2322.
33. 33. Cantin, A. M., S. L. North, R. C. Hubbard, and R. G. Crystal. 1987. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 63:152-157.
34. 34. Durant, J. R., M. J. Norgard, T. M. Murad, A. A. Bartolucci, and K. H. Langford. 1979. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann. Intern. Med. 90:191-194.
35. 35. Selker, R. G., S. A. Jacobs, P. B. Moore, M. Wald, E. R. Fisher, M. Cohen, and P. Bellot. 1980. 1,3-Bis(2-chloroethyl)-1-nitrosurea (BCNU)-induced pulmonary fibrosis. Neurosurgery 7:560-565.